Tarek El Hindi , Suvaporn Anugulruengkitt , Keswadee Lapphra , Kriengsak Limkittikul , Auchara Tangsathapornpong , Claudia M. Galindo , Michael Hellwig , Nicholas Roubinis , Ron Schuring , Shibadas Biswal , Nicolas Folschweiller
{"title":"“与重组9价人乳头瘤病毒疫苗联合使用的四价登革热减毒活疫苗(TAK-003)的免疫原性和安全性”[疫苗62(2025)127558]的勘误","authors":"Tarek El Hindi , Suvaporn Anugulruengkitt , Keswadee Lapphra , Kriengsak Limkittikul , Auchara Tangsathapornpong , Claudia M. Galindo , Michael Hellwig , Nicholas Roubinis , Ron Schuring , Shibadas Biswal , Nicolas Folschweiller","doi":"10.1016/j.vaccine.2025.127785","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":23491,"journal":{"name":"Vaccine","volume":"65 ","pages":"Article 127785"},"PeriodicalIF":4.5000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]\",\"authors\":\"Tarek El Hindi , Suvaporn Anugulruengkitt , Keswadee Lapphra , Kriengsak Limkittikul , Auchara Tangsathapornpong , Claudia M. Galindo , Michael Hellwig , Nicholas Roubinis , Ron Schuring , Shibadas Biswal , Nicolas Folschweiller\",\"doi\":\"10.1016/j.vaccine.2025.127785\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":23491,\"journal\":{\"name\":\"Vaccine\",\"volume\":\"65 \",\"pages\":\"Article 127785\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0264410X25010825\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0264410X25010825","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Corrigendum to “Immunogenicity and safety of the live-attenuated tetravalent dengue vaccine (TAK-003) co-administered with recombinant 9-valent human papillomavirus vaccine” [Vaccine 62 (2025) 127558]
期刊介绍:
Vaccine is unique in publishing the highest quality science across all disciplines relevant to the field of vaccinology - all original article submissions across basic and clinical research, vaccine manufacturing, history, public policy, behavioral science and ethics, social sciences, safety, and many other related areas are welcomed. The submission categories as given in the Guide for Authors indicate where we receive the most papers. Papers outside these major areas are also welcome and authors are encouraged to contact us with specific questions.